Evommune (EVMN) FCF Margin (2025)
Evommune (EVMN) posted quarterly FCF Margin of 796.63% for Q1 2025.
Powered by 
Analysis
Evommune (EVMN) FCF Margin (2025) Analysis & Trends
Evommune (EVMN) has reported FCF Margin for 1 consecutive years, with 796.63% the latest figure, recorded in Q1 2025.
- In Q1 2025, FCF Margin changed N/A year-over-year to 796.63%; the TTM figure through Mar 2026 stood at 523.41% (changed N/A YoY), while the FY2025 annual figure was 588.28%, up 24434.0% from the prior year.
- FCF Margin steadied at 796.63% in Q1 2025 per EVMN's latest filing.
- Across five years, FCF Margin topped out at 796.63% in Q1 2025 and bottomed at 796.63% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 70.82% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -22.35% |
| 10 | Evommune | 448.44 Mn | 247.65 Mn | - | - |